Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (MRSN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mrsn · stock forecast · 19 analysts (3M) · FMP · updated Mar 26, 2026
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Buy
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$17.00
Consensus
$10.00
-65.6% upside
Low
$3.00
Median: $10 · Last Close: $29.08
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$10.00
-65.6% upside
High Target
$17
-41.5%
Low Target
$3
-89.7%
Current Price
$29.08
as of today
Based on analyst price targets, the MRSN stock price prediction for the next 12 months ranges from $3 to $17. The consensus MRSN price forecast of $10.00 implies -65.6% upside from the current price of $29.08.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $29.15 | ↑ 0.25% |
1-day model range: $29.06–$29.24. Peak: $29.24 (+0.25%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · MRSN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2025-11-13 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2025-11-13 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2025-08-14 | Guggenheim | Maintains | Buy→Buy |
| 2025-08-14 | Truist Securities | Maintains | Buy→Buy |
| 2025-05-16 | Guggenheim | Maintains | Buy→Buy |
| 2025-05-16 | Truist Securities | Maintains | Buy→Buy |
| 2024-08-27 | Citigroup | Maintains | Buy→Buy |
| 2024-08-14 | Baird | Maintains | Neutral→Neutral |
| 2024-03-19 | JP Morgan | Upgrade ↑ | Underweight→Neutral |
Wall Street analysts have recently issued updated ratings on Mersana Therapeutics, Inc. (MRSN) stock. Of the recent 88 rating actions, 9 were upgrades and 12 were downgrades. 19 analysts currently cover MRSN.
Analyst Recommendation Trends
MRSN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$25M
↑ 99.6% YoY
Revenue Next Year
$49M
↑ 93.8% YoY
EPS This Year
$-7.14
EPS Next Year
$-9.59
↑ 34.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast MRSN EPS of $-7.14 for the current fiscal year, based on estimates from 2 analysts. The MRSN revenue forecast is $25M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MRSN stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MRSN price target is $10.00 (-65.6% upside), with an analyst consensus of Buy.
The MRSN short-term stock prediction for tomorrow is $29.15 (+0.25%).
Mersana Therapeutics, Inc. trades on NASDAQ under the ticker MRSN. The MRSN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 58% of covering analysts.
Frequently asked questions
MRSN forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month MRSN price target is $10.00, with a high forecast of $17.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies -65.6% potential upside from the current price of $29.08.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.